Metoclopramide Medical Valley
Antiemetic and prokinetic agent for nausea and vomiting
Quick Facts About Metoclopramide Medical Valley
Key Takeaways About Metoclopramide Medical Valley
- Short-term treatment only: Metoclopramide should not be used for more than 5 days due to the increased risk of tardive dyskinesia and other neurological side effects
- Effective antiemetic: Works by blocking dopamine D2 receptors in the brain's chemoreceptor trigger zone and enhancing gastric motility to relieve nausea and vomiting
- Multiple indications: Used for postoperative nausea, radiation-induced vomiting, migraine-associated nausea, and gastroparesis
- Important drug interactions: Should not be combined with levodopa or other dopamine agonists; caution needed with antipsychotics and sedatives
- Dose-dependent side effects: Use the lowest effective dose for the shortest possible duration; the recommended adult dose is 10 mg up to three times daily
What Is Metoclopramide Medical Valley and What Is It Used For?
Metoclopramide Medical Valley is a prescription antiemetic and prokinetic medication containing metoclopramide hydrochloride 10 mg as film-coated tablets. It is used for the short-term prevention and treatment of nausea and vomiting, including postoperative nausea and vomiting (PONV), radiation-induced emesis, and nausea associated with acute migraine attacks. The maximum recommended treatment duration is 5 days.
Metoclopramide belongs to the class of dopamine D2 receptor antagonists and is classified under ATC code A03FA01 (Propulsives). It has been in clinical use since the 1960s and remains one of the most widely prescribed antiemetic medications globally. The World Health Organization (WHO) includes metoclopramide on its Model List of Essential Medicines, recognizing its importance in healthcare systems worldwide.
The medication works through a dual mechanism of action. In the central nervous system, metoclopramide blocks dopamine D2 receptors in the chemoreceptor trigger zone (CTZ) of the medulla oblongata, the region of the brain responsible for triggering nausea and vomiting. In the gastrointestinal tract, it enhances the coordinated contractions of the upper digestive system, increases lower esophageal sphincter tone, relaxes the pyloric sphincter, and accelerates gastric emptying. This combination of central antiemetic and peripheral prokinetic effects makes metoclopramide uniquely effective for conditions involving both nausea and delayed gastric motility.
Metoclopramide Medical Valley is specifically indicated for the following conditions in adults:
- Prevention of postoperative nausea and vomiting (PONV): Administered before or after surgical procedures to prevent nausea and vomiting associated with anesthesia and surgery
- Prevention of radiation-induced nausea and vomiting: Used in patients undergoing radiotherapy to manage treatment-related emesis
- Symptomatic treatment of nausea and vomiting: Including nausea associated with acute migraine attacks, where it also helps improve absorption of oral analgesics such as paracetamol
- Prevention of nausea and vomiting induced by chemotherapy: As part of antiemetic regimens for cancer patients, typically in combination with other antiemetic agents
In children aged 1 to 18 years, metoclopramide is authorized as a second-line treatment for the prevention of delayed chemotherapy-induced nausea and vomiting and for the treatment of established postoperative nausea and vomiting. It is important to note that metoclopramide should not be used in children under 1 year of age due to the increased risk of extrapyramidal disorders.
Although metoclopramide has historically been used for diabetic gastroparesis, current European Medicines Agency (EMA) guidelines restrict its use to a maximum of 5 days. In the United States, the FDA permits longer-term use for gastroparesis (up to 12 weeks) under careful medical supervision. Patients should follow their prescriber's guidance based on local regulations and individual risk assessment.
What Should You Know Before Taking Metoclopramide Medical Valley?
Before taking Metoclopramide Medical Valley, you must inform your doctor about all medical conditions, current medications, and whether you are pregnant or breastfeeding. Metoclopramide is contraindicated in several conditions including pheochromocytoma, mechanical bowel obstruction, and epilepsy. The risk of neurological side effects increases with dose and duration of treatment.
Contraindications
Metoclopramide Medical Valley must not be used in the following situations. If any of these apply to you, your doctor will prescribe an alternative treatment:
- Hypersensitivity to metoclopramide or any of the excipients in the tablet formulation
- Gastrointestinal hemorrhage, mechanical obstruction, or perforation: Metoclopramide stimulates gastric motility, which could worsen these conditions
- Confirmed or suspected pheochromocytoma: Metoclopramide may provoke a hypertensive crisis in patients with this adrenal gland tumor
- History of tardive dyskinesia from neuroleptics or metoclopramide treatment
- Epilepsy: Metoclopramide may increase the frequency and intensity of seizures
- Parkinson's disease: As a dopamine antagonist, metoclopramide can worsen parkinsonian symptoms
- Concurrent use with levodopa or dopaminergic agonists: These drugs have mutually antagonistic effects
- History of methaemoglobinaemia with metoclopramide or NADH cytochrome-b5 reductase deficiency
- Prolactin-releasing pituitary tumor (prolactinoma): Metoclopramide increases prolactin levels
Warnings and Precautions
Several important warnings apply to the use of metoclopramide. Discuss these thoroughly with your prescriber before starting treatment:
Neurological effects: Extrapyramidal symptoms (EPS) such as acute dystonia, akathisia, and parkinsonism may occur, particularly in children, young adults, and elderly patients. These symptoms typically resolve after discontinuation. Tardive dyskinesia, which may be irreversible, can develop during prolonged treatment. For this reason, treatment should not exceed 5 days and the lowest effective dose should always be used.
Neuroleptic Malignant Syndrome (NMS): In rare cases, metoclopramide can cause NMS, a potentially life-threatening condition characterized by hyperthermia, altered consciousness, muscular rigidity, and autonomic dysfunction. If NMS is suspected, metoclopramide must be discontinued immediately and intensive supportive treatment initiated.
Cardiovascular effects: Cases of severe cardiovascular adverse reactions, including hypotension and bradycardia, have been reported, particularly with injectable formulations. Caution is advised in patients with underlying cardiac conduction disorders, uncorrected electrolyte imbalances, or those taking other medications that prolong the QT interval.
Renal and hepatic impairment: In patients with severe renal impairment (creatinine clearance below 15 mL/min), the dose should be reduced by 75%. In patients with moderate to severe hepatic impairment, dose reduction of 50% is recommended, as metoclopramide is primarily metabolized in the liver.
Stop taking metoclopramide and seek immediate medical attention if you experience involuntary movements of your face, tongue, mouth, or jaw (such as tongue protrusion, chewing movements, puffing of cheeks, or lip puckering). These may be signs of tardive dyskinesia, which can become permanent if treatment is not stopped promptly.
Pregnancy and Breastfeeding
The use of metoclopramide during pregnancy requires careful consideration of the benefits and risks. Large epidemiological studies involving thousands of exposed pregnancies have not demonstrated an increased risk of congenital malformations or fetotoxicity. Metoclopramide may be used during pregnancy if clinically necessary, but the lowest effective dose for the shortest duration should be employed.
However, if metoclopramide is used near the end of pregnancy, the newborn should be monitored for extrapyramidal symptoms. The pharmacological properties of metoclopramide (dopamine receptor blockade) mean that extrapyramidal syndrome may theoretically occur in neonates exposed in utero during the third trimester.
Metoclopramide is excreted in breast milk at levels approximately equivalent to those in maternal plasma. Adverse effects in breastfed infants cannot be excluded. Therefore, metoclopramide is generally not recommended during breastfeeding. If use is considered clinically necessary, breastfeeding should be discontinued during treatment.
How Does Metoclopramide Medical Valley Interact with Other Drugs?
Metoclopramide has clinically significant interactions with numerous medications. It must not be combined with levodopa or dopamine agonists due to mutual antagonism. Its prokinetic effects can alter the absorption of other oral medications, and combining it with drugs that affect the central nervous system can lead to enhanced sedation or increased risk of extrapyramidal symptoms.
Understanding drug interactions is critical for safe use of metoclopramide. Because it affects both the central nervous system and gastrointestinal motility, the potential for interactions is broad. Always inform your doctor and pharmacist about all medications you are currently taking, including prescription drugs, over-the-counter medicines, and herbal supplements.
Major Interactions (Contraindicated or Avoid)
| Drug / Drug Class | Interaction Type | Clinical Effect | Recommendation |
|---|---|---|---|
| Levodopa / Dopamine agonists | Pharmacodynamic | Mutual antagonism; reduced efficacy of both drugs | Contraindicated - do not combine |
| Antipsychotics (e.g., haloperidol, chlorpromazine) | Pharmacodynamic | Increased risk of extrapyramidal symptoms | Avoid combination |
| Anticholinergic agents (e.g., atropine) | Pharmacodynamic | Anticholinergics antagonize the prokinetic effects of metoclopramide | Avoid combination |
| Serotonergic drugs (SSRIs, SNRIs) | Pharmacodynamic | Increased risk of serotonin syndrome | Use with extreme caution; monitor closely |
Moderate and Minor Interactions
| Drug / Drug Class | Interaction Type | Clinical Effect | Recommendation |
|---|---|---|---|
| Opioid analgesics (morphine, codeine) | Pharmacodynamic | Opioids antagonize prokinetic effects; enhanced sedation | Monitor; dose adjustment may be needed |
| CNS depressants (benzodiazepines, alcohol) | Pharmacodynamic | Enhanced sedation and drowsiness | Avoid alcohol; use caution with sedatives |
| Digoxin | Pharmacokinetic | Decreased digoxin absorption and bioavailability | Monitor digoxin levels |
| Ciclosporin | Pharmacokinetic | Increased ciclosporin absorption and bioavailability | Monitor ciclosporin blood levels closely |
| Paracetamol (Acetaminophen) | Pharmacokinetic | Increased rate of paracetamol absorption | Generally beneficial in migraine; no dose change needed |
| Strong CYP2D6 inhibitors (fluoxetine, paroxetine) | Pharmacokinetic | Increased metoclopramide plasma levels | Consider dose reduction of metoclopramide |
Metoclopramide accelerates gastric emptying, which means it can alter the rate and extent of absorption of other orally administered drugs. Medications that are primarily absorbed in the stomach may have reduced bioavailability, while those absorbed in the small intestine may have increased absorption rates. This is an important consideration for drugs with narrow therapeutic indices.
What Is the Correct Dosage of Metoclopramide Medical Valley?
The standard adult dose of Metoclopramide Medical Valley is 10 mg (one tablet) up to three times daily. The maximum treatment duration is 5 days. Doses should be taken with a minimum interval of 6 hours. The maximum daily dose for adults is 30 mg or 0.5 mg/kg body weight, whichever is lower. Dose reduction is necessary in patients with renal or hepatic impairment.
Correct dosing of metoclopramide is essential for both efficacy and safety. The risk of adverse neurological effects is directly related to the dose and duration of treatment. Your doctor will determine the appropriate dose based on your clinical indication, age, weight, and kidney and liver function.
Adults (18 years and older)
Standard Adult Dosing
Dose: 10 mg (one film-coated tablet) up to three times daily
Maximum daily dose: 30 mg or 0.5 mg/kg body weight (whichever is lower)
Minimum interval between doses: 6 hours
Maximum treatment duration: 5 days
Administration: Take tablets 30 minutes before meals with a glass of water. For postoperative nausea prevention, the first dose may be given before surgery.
Children and Adolescents (1-18 years)
Pediatric Dosing
Dose: 0.1 to 0.15 mg/kg body weight, up to three times daily by oral route
Maximum daily dose: 0.5 mg/kg body weight
Minimum interval between doses: 6 hours
Note: The 10 mg film-coated tablet formulation is generally not suitable for precise pediatric dosing. Liquid formulations may be more appropriate for children. Metoclopramide is contraindicated in children under 1 year of age.
| Patient Group | Recommended Dose | Maximum Daily Dose | Special Considerations |
|---|---|---|---|
| Healthy adults | 10 mg up to 3 times daily | 30 mg | Maximum 5 days treatment |
| Elderly (65+ years) | 5 mg up to 3 times daily | 15 mg | Start at lower dose; higher EPS risk |
| Severe renal impairment (CrCl <15 mL/min) | 2.5 mg up to 3 times daily | 7.5 mg | 75% dose reduction required |
| Moderate renal impairment (CrCl 15-60 mL/min) | 5 mg up to 3 times daily | 15 mg | 50% dose reduction recommended |
| Hepatic impairment | 5 mg up to 3 times daily | 15 mg | 50% dose reduction; monitor closely |
| Children (1-18 years) | 0.1-0.15 mg/kg up to 3 times daily | 0.5 mg/kg | Liquid formulation preferred; second-line only |
Elderly Patients
Dose reduction should be considered in elderly patients based on renal and hepatic function as well as overall clinical condition. Elderly patients are at increased risk of extrapyramidal symptoms, tardive dyskinesia, and other adverse effects. A starting dose of 5 mg three times daily is generally recommended, with careful monitoring for neurological side effects. The risk-benefit ratio should be regularly reassessed, especially since elderly patients are more likely to have comorbidities and take multiple medications that may interact with metoclopramide.
Missed Dose
If you forget to take a dose of Metoclopramide Medical Valley, take it as soon as you remember. However, if it is nearly time for your next dose (less than 6 hours until the next scheduled dose), skip the missed dose and take your next dose at the regular time. Never take a double dose to compensate for a missed one. The minimum interval between consecutive doses must always be maintained at 6 hours to minimize the risk of adverse effects.
Overdose
An overdose of metoclopramide can cause significant symptoms including extrapyramidal disorders, drowsiness, reduced level of consciousness, confusion, hallucinations, and cardiovascular effects such as bradycardia and changes in blood pressure. In severe overdose, respiratory arrest may occur.
If you suspect an overdose of metoclopramide, seek emergency medical attention immediately. Contact your local poison control center or go to the nearest emergency department. Treatment is primarily symptomatic and supportive. Extrapyramidal symptoms may be treated with anticholinergic agents (such as biperiden) or benzodiazepines. There is no specific antidote for metoclopramide overdose.
What Are the Side Effects of Metoclopramide Medical Valley?
Like all medicines, Metoclopramide Medical Valley can cause side effects, although not everybody gets them. The most common side effects include drowsiness, fatigue, restlessness, and diarrhea. More serious but less common effects include extrapyramidal symptoms (involuntary movements), tardive dyskinesia, and neuroleptic malignant syndrome. The risk of neurological side effects increases with higher doses and longer treatment duration.
Side effects of metoclopramide are generally dose-dependent and time-dependent. Most adverse reactions resolve after discontinuation of the medication. However, certain neurological effects, particularly tardive dyskinesia, may be irreversible. Below is a comprehensive overview of reported side effects organized by frequency according to international pharmacovigilance standards.
Very Common (affects more than 1 in 10 patients)
- Drowsiness and somnolence
Common (affects 1 to 10 in 100 patients)
- Extrapyramidal symptoms (especially in children and young adults): acute dystonia, akathisia, parkinsonism
- Depression
- Fatigue and asthenia (weakness)
- Restlessness
- Diarrhea
- Hypotension (low blood pressure)
- Hyperprolactinaemia (elevated prolactin levels) which may cause amenorrhoea, galactorrhoea, or gynaecomastia
Uncommon (affects 1 to 10 in 1,000 patients)
- Hallucinations
- Reduced level of consciousness
- Bradycardia (slow heart rate)
- Allergic reactions including rash and urticaria
- Amenorrhoea (absence of menstrual periods)
- Galactorrhoea (unexpected breast milk production)
Rare and Very Rare (affects fewer than 1 in 1,000 patients)
- Tardive dyskinesia (potentially irreversible involuntary facial movements)
- Neuroleptic Malignant Syndrome (NMS) - a medical emergency
- Methaemoglobinaemia (especially in neonates with NADH cytochrome-b5 reductase deficiency)
- Anaphylactic shock
- Cardiac arrest (primarily with injectable form)
- QT prolongation and torsades de pointes
- Sulfhaemoglobinaemia
- Seizures
Extrapyramidal symptoms deserve special attention. These include involuntary muscle spasms (dystonia) that can affect the face, neck, and trunk; a distressing inner restlessness called akathisia; and parkinsonian features such as tremor, rigidity, and slowness of movement. These symptoms are more common in children and young adults and usually occur within the first 24-48 hours of treatment. Most acute extrapyramidal reactions respond to withdrawal of the drug and, if necessary, treatment with anticholinergic medications.
Tardive dyskinesia is the most feared adverse effect of metoclopramide. It typically manifests as repetitive, involuntary movements of the tongue, face, mouth, or jaw, and sometimes includes involuntary movements of the trunk and extremities. The risk increases with treatment duration and cumulative dose, which is why the current recommended maximum treatment duration is 5 days. Elderly patients, particularly elderly women, are at greatest risk. Tardive dyskinesia may be partially or completely irreversible.
Contact your doctor or seek emergency medical care immediately if you experience: high fever with muscle stiffness and altered consciousness (possible NMS), involuntary facial or tongue movements (possible tardive dyskinesia), severe allergic reaction with swelling of the face or difficulty breathing, or unusual changes in heart rhythm. These require urgent medical assessment.
How Should You Store Metoclopramide Medical Valley?
Store Metoclopramide Medical Valley at room temperature below 25°C (77°F) in the original packaging to protect from light and moisture. Keep out of sight and reach of children. Do not use after the expiry date stated on the packaging.
Proper storage of medications is essential for maintaining their effectiveness and safety. Metoclopramide Medical Valley film-coated tablets should be stored under the following conditions:
- Temperature: Store below 25°C (77°F). Do not freeze. Avoid exposure to excessive heat or direct sunlight.
- Light protection: Keep the tablets in the original blister packaging or container to protect from light, as metoclopramide can be affected by prolonged light exposure.
- Moisture: Store in a dry place. Do not store in the bathroom or other humid environments, as moisture can degrade the film coating and active ingredient.
- Child safety: Keep this medicine out of the sight and reach of children. Consider using a child-resistant storage location or container.
- Expiry date: Do not use Metoclopramide Medical Valley after the expiry date stated on the carton and blister. The expiry date refers to the last day of that month.
Do not dispose of unused medications via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. Proper disposal helps protect the environment and prevents accidental exposure. Many communities offer pharmaceutical take-back programs for safe medication disposal.
What Does Metoclopramide Medical Valley Contain?
Each Metoclopramide Medical Valley film-coated tablet contains 10 mg of metoclopramide hydrochloride as the active substance. The tablets also contain several inactive ingredients (excipients) that contribute to the tablet's physical properties, stability, and appearance.
Understanding the complete composition of your medication is important, particularly if you have known allergies or intolerances to specific ingredients. The full composition of Metoclopramide Medical Valley 10 mg film-coated tablets is as follows:
Active substance:
- Metoclopramide hydrochloride 10 mg (equivalent to approximately 8.4 mg metoclopramide base)
Excipients (inactive ingredients):
The tablet core and film coating contain standard pharmaceutical excipients. Common excipients used in metoclopramide film-coated tablet formulations include:
- Tablet core: Lactose monohydrate, microcrystalline cellulose, croscarmellose sodium (disintegrant), magnesium stearate (lubricant), colloidal anhydrous silica (glidant)
- Film coating: Hypromellose (hydroxypropyl methylcellulose), titanium dioxide (E171), macrogol/polyethylene glycol
Metoclopramide Medical Valley tablets contain lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Appearance: Metoclopramide Medical Valley 10 mg tablets are white to off-white, round, film-coated tablets. They may be scored to allow for dose division if prescribed by your doctor.
Frequently Asked Questions About Metoclopramide Medical Valley
Metoclopramide Medical Valley is a prescription antiemetic and prokinetic medication used for the short-term prevention and treatment of nausea and vomiting. Its main indications include postoperative nausea and vomiting (PONV), radiation-induced emesis, nausea associated with acute migraine attacks (where it also enhances absorption of oral painkillers), and as part of chemotherapy-induced nausea regimens. Treatment should not exceed 5 days in most clinical settings.
The recommended maximum treatment duration for Metoclopramide Medical Valley is 5 days. This restriction was introduced by the European Medicines Agency (EMA) following a comprehensive safety review that confirmed the risk of neurological side effects, particularly tardive dyskinesia, increases significantly with longer treatment duration and higher cumulative doses. Your doctor may prescribe it for shorter periods depending on your clinical needs. Never exceed the prescribed duration without medical supervision.
The most serious side effects of metoclopramide include tardive dyskinesia (involuntary repetitive movements of the face, tongue, and jaw that may be irreversible), neuroleptic malignant syndrome (a rare but life-threatening condition with high fever, muscle rigidity, and altered consciousness), and severe extrapyramidal reactions such as acute dystonia (painful muscle spasms). If you experience any involuntary movements, high fever with muscle stiffness, or difficulty breathing, seek emergency medical attention immediately.
Metoclopramide can cause drowsiness, dizziness, and dystonia, which may impair your ability to drive or operate machinery safely. You should avoid driving or using dangerous machinery until you know how metoclopramide affects you. If you experience any drowsiness or visual disturbances, do not drive or operate heavy equipment. The sedative effects may be enhanced if you consume alcohol or take other central nervous system depressants at the same time.
No, you should avoid drinking alcohol while taking metoclopramide. Alcohol enhances the sedative effects of metoclopramide, leading to increased drowsiness and reduced alertness. This combination can significantly impair your ability to drive, concentrate, and perform tasks requiring mental alertness. Additionally, alcohol itself can irritate the stomach lining and worsen nausea, counteracting the therapeutic purpose of the medication.
If you miss a dose of Metoclopramide Medical Valley, take it as soon as you remember. However, if it is less than 6 hours until your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Never take two doses at the same time or take extra doses to make up for a missed one. The minimum 6-hour interval between doses must be maintained to reduce the risk of side effects. If you are unsure, consult your pharmacist or doctor.
References and Sources
All medical information in this article is based on internationally recognized guidelines, peer-reviewed research, and official drug regulatory documentation. iMedic has no commercial relationships with pharmaceutical companies and receives no funding from the pharmaceutical industry.
- European Medicines Agency (EMA). (2014). PRAC recommends restricting the use of metoclopramide. EMA/443003/2013. Assessment of the benefit-risk balance leading to current prescribing restrictions.
- World Health Organization (WHO). (2023). WHO Model List of Essential Medicines - 23rd List. Geneva: WHO. Metoclopramide listed as an essential antiemetic medicine.
- Rao, A. S., & Camilleri, M. (2010). Review article: metoclopramide and tardive dyskinesia. Alimentary Pharmacology & Therapeutics, 31(1), 11-19.
- Ehrenpreis, E. D., et al. (2009). Metoclopramide-induced tardive dyskinesia in the elderly: clinically relevant data. American Journal of Gastroenterology, 104(3), 740-743.
- British National Formulary (BNF). (2025). Metoclopramide hydrochloride. National Institute for Health and Care Excellence (NICE). Current prescribing guidance and safety information.
- U.S. Food and Drug Administration (FDA). (2009). FDA requires boxed warning and risk mitigation strategy for metoclopramide-containing drugs. FDA Drug Safety Communication.
- Parkman, H. P., et al. (2010). Clinical response and side effects of metoclopramide: associations with clinical, demographic, and pharmacogenetic parameters. Journal of Clinical Gastroenterology, 46(6), 494-503.
- Achem, S. R. (2008). Treatment of spastic esophageal motility disorders. Gastroenterology Clinics of North America, 33(1), 107-124.
- Reddymasu, S. C., et al. (2007). Domperidone: review of pharmacology and clinical applications in gastroenterology. American Journal of Gastroenterology, 102(9), 2036-2045.
- Lau Moon Lin, M., et al. (2016). Pharmacogenomics of metoclopramide-induced tardive dyskinesia: systematic review and meta-analysis. Pharmacogenomics, 17(18), 2087-2098.
About Our Medical Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, which includes licensed specialist physicians in pharmacology, gastroenterology, and clinical medicine. Our editorial process follows international standards for medical content production:
All medical claims are supported by peer-reviewed research using the GRADE evidence framework. We prioritize systematic reviews, meta-analyses, and randomized controlled trials (Level 1A evidence).
Content is independently reviewed by our Medical Review Board. We have no financial relationships with pharmaceutical companies, and all content is produced without commercial influence.
We adhere to WHO, EMA, and FDA guidelines and cross-reference multiple authoritative sources including the British National Formulary (BNF) and Cochrane Library.
Articles are reviewed at least annually or whenever significant new evidence, safety alerts, or regulatory changes are published by major drug regulatory authorities.